Lista de obras -

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

artículo científico publicado en 2013

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

artículo científico publicado en 2024

Covalent-Allosteric Kinase Inhibitors.

artículo científico publicado en 2015

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

artículo científico publicado en 2013

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor

artículo científico publicado en 2017

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

artículo científico publicado en 2015

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib

scientific article published on 04 May 2016

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

artículo científico publicado en 2017

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR

artículo científico publicado en 2016

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy

artículo científico publicado en 2019

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

artículo científico publicado en 2014

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells

artículo científico publicado en 2009

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour

scientific article published on 17 February 2012

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain

scientific article published on 24 September 2020

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

artículo científico publicado en 2013

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors

artículo científico publicado en 2012

Lista de obras de

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

Covalent-Allosteric Kinase Inhibitors.

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor

Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors